Article Menu

Export Article

More by Authors Links

Article Data

  • Views 4036
  • Dowloads 268

Editorials

Open Access Special Issue

Molecular markers and endometrial cancer

  • Ottavia D’Oria1
  • Giorgio Bogani2
  • Enrico Vizza3
  • Vito Chiantera4
  • Ludovico Muzii2
  • Maria Giovanna Salerno5
  • Donatella Caserta6
  • Antonio Simone Laganà4
  • Andrea Tinelli7
  • Giacomo Corrado8
  • Andrea Giannini1,*,

1Department of Medical and Surgical Sciences and Translational Medicine, PhD Course in “Translational Medicine and Oncology”, Sapienza University, 00189 Rome, Italy

2Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00160 Rome, Italy

3Gynecologic Oncology Unit, Department of Experimental Clinical Oncology, IRCCS-Regina Elena National Cancer Unit Institute, 00144 Rome, Italy

4Unit of Gynecologic Oncology, ARNAS “Civico–Di Cristina–Benfratelli”, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy

5Department of Woman’s and Child’s Health, Obstetrics and Gynecological Unit, San Camillo-Forlanini Hospital, 00152 Rome, Italy

6Gynecology Division, Department of Medical and Surgical Sciences and Translational Medicine, Sant’Andrea University Hospital, Sapienza University of Rome, 00189 Rome, Italy

7Department of Gynecology and Obstetrics, Division of Experimental Endoscopic Surgery, Imaging, Minimally Invasive Therapy and Technology, Vito Fazzi Hospital, 73100 Lecce, Italy

8Woman, Child and Public Health Department, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Rome, Italy

DOI: 10.22514/ejgo.2022.051 Vol.43,Issue 6,December 2022 pp.1-3

Submitted: 05 September 2022 Accepted: 20 October 2022

Published: 15 December 2022

*Corresponding Author(s): Andrea Giannini E-mail: andrea.giannini@uniroma1.it

PDF (272.64 kB) View Full-text

Cite and Share

Ottavia D’Oria,Giorgio Bogani,Enrico Vizza,Vito Chiantera,Ludovico Muzii,Maria Giovanna Salerno,Donatella Caserta,Antonio Simone Laganà,Andrea Tinelli,Giacomo Corrado,Andrea Giannini. Molecular markers and endometrial cancer. European Journal of Gynaecological Oncology. 2022. 43(6);1-3.

URL:

https://www.ejgo.net/articles/10.22514/ejgo.2022.051

References

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. A Cancer Journal for Clinicians. 2021; 71: 209–249.

[2] Laganà AS. Management of endometrial cancer: current insights and future directions. Translational Cancer Research. 2020; 9: 7685–7687.

[3] Králíčková M, Vetvicka V, Laganà AS. Endometrial cancer—is our knowledge changing? Translational Cancer Research. 2020; 9: 7734–7745.

[4] Li L, Chen F, Liu J, Zhu W, Lin L, Chen L, et al. Molecular classification grade 3 endometrial endometrioid carcinoma using a next-generation sequencing-based gene panel. Frontiers in Oncology. 2022; 12: 935694.

[5] Bianco B, Barbosa CP, Trevisan CM, Laganà AS, Montagna E. Endometrial cancer: a genetic point of view. Translational Cancer Research. 2020; 9: 7706–7715.

[6] Cancer Genome Atlas Research Network; Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497: 67–73.

[7] Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, et al. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017; 123: 802–813.

[8] Bogani G, Dowdy SC, Cliby WA, Ghezzi F, Rossetti D, Frigerio L, et al. European Journal of Gynaecological Oncology. 2016; 37: 6–12.

[9] Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, et al. Uterine serous carcinoma. Gynecologic Oncology. 2021; 162: 226–234.

[10] Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, et al. Clear cell carcinoma of the endometrium. Gynecologic Oncology. 2022; 164: 658–666.

[11] Stelloo E, Nout RA, Osse EM, Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer—combined analysis of the PORTEC cohorts. Clinical Cancer Research. 2016; 22: 4215–4224.

[12] León-Castillo A, de Boer SM, Powell ME, Mileshkin LR, Mackay HJ, Leary A, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. Journal of Clinical Oncology. 2020; 38: 3388–3397.

[13] Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal of Gynecological Cancer. 2021; 31: 12–39.

[14] Köbel M, Ronnett BM, Singh N, Soslow RA, Gilks CB, McCluggage WG. Interpretation of P53 immunohistochemistry in endometrial carcinomas. International Journal of Gynecological Pathology. 2019; 38: S123–S131.

[15] Vizza E, Bruno V, Cutillo G, Mancini E, Sperduti I, Patrizi L, et al. Prognostic role of the removed vaginal cuff and its correlation with L1CAM in low-risk endometrial adenocarcinoma. Cancers. 2021; 14: 34.

[16] Di Tucci C, Schiavi MC, Faiano P, D’Oria O, Prata G, Sciuga V, et al. Therapeutic vaccines and immune checkpoints inhibition options for gynecological cancers. Critical Reviews in Oncology/Hematology. 2018; 128: 30–42.

[17] Benati M, Montagnana M, Danese E, Mazzon M, Paviati E, Garzon S, et al. Aberrant telomere length in circulating cell-free DNA as possible blood biomarker with high diagnostic performance in endometrial cancer. Pathology & Oncology Research. 2020; 26: 2281–2289.

[18] Ura B, Capaci V, Aloisio M, Di Lorenzo G, Romano F, Ricci G, et al. Targeted proteomics approach for screening serum biomarkers observed in the early stage of type I endometrial cancer. Biomedicines. 2022; 10: 1857.

[19] Liew P, Huang R, Wu T, Liao C, Chen C, Su P, et al. Combined genetic mutations and DNA-methylated genes as biomarkers for endometrial cancer detection from cervical scrapings. Clinical Epigenetics. 2019; 11: 170.

[20] Huang R, Su P, Liao Y, Wu T, Hsu Y, Lin W, et al. Integrated epigenomics analysis reveals a DNA methylation panel for endometrial cancer detection using cervical scrapings. Clinical Cancer Research. 2017; 23: 263–272.


Submission Turnaround Time

Top